Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.57 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.57 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.55 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29678875 | 0.89 | MAPT (0.64) | MAPTKMT2AALDH1A1MEN1KDM4E | |
| SCHEMBL5169870 | 0.89 | MAPT (0.64) | MAPTKMT2AALDH1A1MEN1KDM4E | |
| SCHEMBL6931187 | 0.87 | CYP1A2 (0.63) | MAPTKMT2AALDH1A1MEN1KDM4E | |
| SCHEMBL12595464 | 0.87 | HDAC1 (0.57) | HDAC1HDAC6AKR1C3AKR1C2MAPT | |
| SCHEMBL30462572 | 0.87 | HDAC1 (0.57) | HDAC1HDAC6AKR1C3AKR1C2MAPT | |
| SCHEMBL13897134 | 0.86 | RAB9A (0.49) | HDAC1HDAC6AKR1C3AKR1C2MAPT | |
| SCHEMBL1561739 | 0.86 | MAPT (0.60) | HDAC1HDAC6AKR1C3AKR1C2MAPT | |
| SCHEMBL30456978 | 0.86 | CA12 (0.65) | AKR1C3AKR1C2MAPTKMT2AALDH1A1 | |
| SCHEMBL5168276 | 0.86 | CA12 (0.65) | AKR1C3AKR1C2MAPTKMT2AALDH1A1 | |
| SCHEMBL423047 | 0.86 | KMT2A (0.60) | HDAC1HDAC6AKR1C3AKR1C2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3881048-B1 | DEVICE FOR REMOVING VOLATILE ORGANIC COMPOUNDS | LETAT FRANCAIS REPRESENTE PAR LE MINI DE LINTERIEUR (FR) | 2026-05-06 | — | — | EP | disclosed |
| US-20220170904-A1 | SYSTEMS AND METHODS FOR MONITORING BIOLOGICAL TISSUE DEGRADATION | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2022-06-02 | — | — | US | disclosed |
| US-20210396629-A1 | DEVICE FOR COLLECTING VOLATILE ORGANIC COMPOUNDS | L'ETAT FRANÇAIS REPRÉSENTÉ PAR LE MINISTÈRE DE L'INTÉRIEUR (FR) | 2021-12-23 | — | — | US | disclosed |
| EP-3881048-A1 | DEVICE FOR REMOVING VOLATILE ORGANIC COMPOUNDS | L'etat Français Représenté Par Le Ministère De L'intérieur (FR) | 2021-09-22 | — | — | EP | disclosed |
| CN-113167695-A | Device for collecting volatile organic compounds | 法国由内政部代表 | 2021-07-23 | — | — | CN | disclosed |
| WO-2020099735-A1 | DEVICE FOR REMOVING VOLATILE ORGANIC COMPOUNDS | L'ETAT FRANÇAIS REPRÉSENTÉ PAR LE MINISTÈRE DE L'INTÉRIEUR (FR) | 2020-05-22 | — | — | WO | disclosed |
| US-9133073-B2 | Compounds for the treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORPORATION (US) | 2015-09-15 | — | — | US | disclosed |
| US-8604083-B2 | Method for the treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORPORATION (US) | 2013-12-10 | — | — | US | disclosed |
| US-20130281705-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORP (US) | 2013-10-24 | — | — | US | disclosed |
| US-8552062-B2 | Methods for the treatment of metabolic disorders such as diabetes | WELLSTAT THERAPEUTICS CORPORATION (US) | 2013-10-08 | — | — | US | disclosed |
| US-20030149107-A1 | Compounds for the treatment of metabolic disorders | PHARMA CINQ, LLC | 2003-08-07 | — | — | US | disclosed |
| EP-1289980-A1 | BICYCLYL OR HETEROBICYCLYLMETHANESULFONYLAMINO-SUBSTITUTED N-HYDROXYFORMAMIDES | SMITHKLINE BEECHAM PLC (GB) | 2003-03-12 | — | — | EP | disclosed |
| WO-2002100341-A2 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORPORATION (US) | 2002-12-19 | — | — | WO | disclosed |
| WO-2001090100-A1 | BICYCLYL OR HETEROBICYCLYLMETHANESULFONYLAMINO-SUBSTITUTED N-HYDROXYFORMAMIDES | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-11-29 | — | — | WO | disclosed |
| EP-0733037-A1 | ARYL SUBSTITUTED AMINO ACIDS, CNS INFLUENCING AGENTS | UNIVERSITY OF BRISTOL (GB) | 1996-09-25 | — | — | EP | disclosed |
| US-5502187-A | Pharmaceutically active bicyclic-heterocyclic amines | THE UPJOHN COMPANY (US) | 1996-03-26 | — | — | US | disclosed |
| WO-1995015941-A1 | ARYL SUBSTITUTED AMINO ACIDS, CNS INFLUENCING AGENTS | UNIVERSITY OF BRISTOL (GB) | 1995-06-15 | — | — | WO | disclosed |
| EP-0633886-A1 | PHARMACEUTICALLY ACTIVE BICYCLIC-HETEROCYCLIC AMINES | PHARMACIA & UPJOHN COMPANY (US) | 1995-01-18 | — | — | EP | disclosed |
| WO-1993020078-A1 | PHARMACEUTICALLY ACTIVE BICYCLIC-HETEROCYCLIC AMINES | THE UPJOHN COMPANY (US) | 1993-10-14 | — | — | WO | disclosed |
| US-4221808-A | Novel antihypertensive agent | RICHARDSON-MERRELL INC. (US) | 1980-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281705-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | GOT2, OAT, CPT1B | HDAC1 1030/4885HDAC6 1460/4885AKR1C3 349/4885 |
| US-20030149107-A1 | Compounds for the treatment of metabolic disorders | GOT2, OAT, CPT1B | HDAC1 1030/4885HDAC6 1460/4885AKR1C3 349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.